The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The need for disease-modifying agents in PV to prevent disease progression
Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, highlights the need to find a therapeutic strategy that allows changing the disease course in patients with polycythemia vera (PV) in order to prevent disease progression and improve patient outcomes, commenting on recent data on ropeginterferon alfa-2b. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
